Market Place
Sourcing Support
NeuroBo Reports Positive Data From DA-1726 Trial For Obesity
30 Sep 2024 //
PR NEWSWIRE
NeuroBo to Participate in H.C. Wainwright Global Investment Conference
03 Sep 2024 //
PR NEWSWIRE
NeuroBo Reports Q2 2024 Results And Provides Corporate Update
14 Aug 2024 //
PR NEWSWIRE
NeuroBo Signs Exclusive License Agreement with MTHERA for NB-01
30 Jul 2024 //
CONTRACT PHARMA
NeuroBo Closes Up to $70M Concurrent Private Placement and Registered Offering
25 Jun 2024 //
PR NEWSWIRE
NeuroBo Pharmaceuticals Announces $70M Private Placement And Direct Offering
24 Jun 2024 //
PR NEWSWIRE
NeuroBo Pharma Q1 2024 Financials, Corporate Update
09 May 2024 //
PR NEWSWIRE
NeuroBo Doses First Patient in Obesity Trial for DA-1726
17 Apr 2024 //
PR NEWSWIRE
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results
28 Mar 2024 //
PR NEWSWIRE
NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference
12 Feb 2024 //
PRESS RELEASE
NeuroBo Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726
01 Feb 2024 //
PRESS RELEASE
NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241
18 Jan 2024 //
PR NEWSWIRE
NeuroBo Pharma Regains Compliance with Nasdaq Minimum Price Requirement
09 Jan 2024 //
PR NEWSWIRE
NeuroBo to Participate in Industry and Investor Conferences in January
02 Jan 2024 //
PRESS RELEASE
NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split
19 Dec 2023 //
PR NEWSWIRE
NeuroBo to Participate in Investor Conferences in December
01 Dec 2023 //
PR NEWSWIRE
NeuroBo Strengthens Board of Directors with the Appointment of James P. Tursi
06 Nov 2023 //
PR NEWSWIRE
NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
PR NEWSWIRE
NeuroBo Pharma Enters Into Term Sheet With MThera Pharma to Out-license NB-01
02 Aug 2023 //
PR NEWSWIRE
NeuroBo Pharma` Novel GLP1R and GCGR Dual Agonist, DA-1726
27 Jun 2023 //
PR NEWSWIRE
NeuroBo Announces Acceptance of Theater Discussion of DA-1726
13 Jun 2023 //
PR NEWSWIRE
NeuroBo Pharma Appoints Pharmaceutical Industry Executive, Mark A. Glickman, BOD
12 May 2023 //
PR NEWSWIRE
FDA clears NeuroBo IND to start two-part Phase IIa NASH therapy trial
03 May 2023 //
CLINICAL TRIALS ARENA
NeuroBo Announces Submission of IND to FDA for a Phase 2a Trial of DA-1241
03 Apr 2023 //
PR NEWSWIRE
NeuroBo Appoints Joseph Hooker as Interim Chief Executive Officer and President
18 Jan 2023 //
PR NEWSWIRE
NeuroBo Announces Closing Of $32.3 Million Underwritten Public Offering
08 Nov 2022 //
PRNEWSWIRE
Neurobo Announces Pricing Of $30 Million Underwritten Public Offering
04 Nov 2022 //
PRNEWSWIRE
Community, NeuroBo healthcare gainers; Taysha, TransCode lead losers` pack
27 Oct 2022 //
SEEKING ALPHA
NeuroBo Pharmaceuticals Compliant with All Applicable Nasdaq Listing Criteria
29 Sep 2022 //
NEUROBOPHARMA
NeuroBo Pharmaceuticals Announces Reverse Stock Split
12 Sep 2022 //
PRNEWSWIRE
NeuroBo Pharma Expands Management Team
06 May 2022 //
PRNEWSWIRE
NeuroBo Pharmaceuticals Reports Third Quarter 2021 Financial Results
15 Nov 2021 //
PRNEWSWIRE
NeuroBo to continue Phase II/III Covid drug trial without modifications
13 Oct 2021 //
CLINICALTRIALSARENA
NeuroBo: +ve Recommendation from Independent Data Safety Monitoring Committee
13 Oct 2021 //
BIOSPACE
NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering
05 Oct 2021 //
PRNEWSWIRE
NeuroBo Pharmaceuticals Announces $14 Million Registered Direct Offering
01 Oct 2021 //
PRNEWSWIRE
NeuroBo Pharmaceuticals` Shareholders Elect Hyung Heon Kim
12 Jul 2021 //
PRNEWSWIRE
NeuroBo Receives Approval for Amendment of Contingent Value Rights
24 Mar 2021 //
PRNEWSWIRE
NeuroBo Acquires ANA Therapeutics for Late-Stage Oral Antiviral
06 Jan 2021 //
PRNEWSWIRE
NeuroBo Announces Continuation of Partial Clinical Hold of Gemcabene
26 May 2020 //
PR NEWSWIRE
NeuroBo Pharma gets US patent entitled "Composition Containing Mixed Extract
22 Apr 2020 //
PHARMABIZ
NeuroBo Pharmaceuticals Announces Issuance of U.S. Patent of NB-02
21 Apr 2020 //
PR NEWSWIRE
